| |
 |
Dr. Jason Wu, MD, MS, MBA, FAAD
Executive Vice President & Chief Medical Officer, WuXiPRA Clinical Research (Shanghai) Co. Ltd.
Shanghai, China |
|
| |
| Biography: |
|
| |
| Dr. Jason Wu has more than 20 years of experiences in clinical practice, life science research and pharmaceutical product development. Dr. Wu conducted more than 40 Phase 1 - 4 clinical trials in North America and contributed to the regulatory approvals of 7 products (Zyvox, Penlac, BenzaClin, Sculptra, Xiaflex, Zyclara, and Vyloma). Dr. Wu obtained 19 patents and published more than 30 scientific papers in the leading international journals covering both clinical and scientific researches. Dr. Wu currently is EVP and CMO at WuXiPRA, a leading China based CRO and the JV between the China largest CRO WuXiAppTec and global 4th largest PRA Health Sciences. Previously he was COO and Sr. VP at Prosoft Clinical, overseeing day to day operations in US and Europe; and GM of Clinical Division and Sr. VP at Frontage Laboratory, a CRO with operations in both US and China. Prior to Frontage, Dr. Wu was Executive Director of Clinical Development at Graceway Pharmaceuticals responsible for product development of several pipelines acquired from 3M. Prior to Graceway, he was Sr. Clinical Project Director at Auxilium Pharmaceuticals leading a team to develop and file a BLA for a biologic product targeting several orphan indications. Dr. Wu held the senior management position at Sanofi-Aventis and led a development program for a new anti-fungal topical product and provided medical affair support for company marketing needs. Dr. Wu also worked for Pharmacia & Upjohn (now Pfizer) as Clinical Research Manager and Team Leader involved in a new antibiotic product FDA filing and responsible for its global Phase 3b program in the United States, he was the Head of South China and Head of the Peptide Hormones Business Unit for P&U in China . Dr. Wu did hematology and human genome research projects under his mentors: Academician Zhu Chen (former China Health Minister) and Saijuan Chen at Shanghai Institute of Hematology. Dr. Wu obtained his MD and MS from Shanghai Jiao Tong University School of Medicine, and his MBA from Pennsylvania State University. He is a fellow member of American Academy of Dermatology and a member of American Society of Microbiology. |
| |
| Session: |
|
| |
| 21st November 2015 (Saturday) |
 |
15:00 – 16:00 |
|
| |
| Session IV: Drug Development in the Pharmaceutical Industry |
| |
| |
| |
| |
| |
|
|
